
Optogenetic Trial Shows Partial Vision Restoration in 10 Patients with Retinitis Pigmentosa
A new study published in the New England Journal of Medicine confirms that optogenetic gene therapy can safely restore partial vision in people with advanced retinitis pigmentosa. In a trial of 10 participants, six showed clinically meaningful improvements in light sensitivity, and some regained the ability to detect objects and navigate simple tasks using custom goggles. The therapy, which leverages Nobel Prize-winning technology, involves a single injection to make surviving ganglion cells light-sensitive. While results are limited to monochrome perception and do not yet restore facial recognition, researchers aim to achieve high-resolution vision within five to 10 years.












